Ultragenyx Pharmaceutical Inc. RARE

Annual Quarterly

Q3 FY2026 · ended Sep 30, 2026 · Revenue $173.00M, +8.1% YoY · Filed Nov 4, 2026

Ultragenyx Pharmaceutical Inc. (RARE) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $173.0 million and a net loss of $118.0 million. Free cash flow was -$45.0 million.

Revenue
$173.00M
+8.1% vs year-ago quarter
Net income
$-118.00M
+34.4% vs year-ago quarter
Operating cash flow
$-43.00M
+52.7% vs year-ago quarter
Free cash flow
$-45.00M
+51.1% vs year-ago quarter
EPS
$-1.16
+35.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
101.92M
+5.6% vs year-ago quarter
Net cash
$701.00M
Q4 FY2025
Operating margin
-64.0%
TTM

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RARE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Novato, CA
SEC filer status
Large accelerated filer
SEC CIK
1515673

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q3 FY2026
Sep 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Revenue
$173.0M
$214.0M
$136.0M
$207.0M
$160.0M
Operating income
-$110.0M
-$75.0M
-$169.0M
-$113.0M
-$171.0M
Net income
-$118.0M
-$92.0M
-$185.0M
-$129.0M
-$180.0M
Diluted EPS
-$1.16
-$0.90
-$1.84
-$1.29
-$1.81
Operating cash flow
-$43.0M
-$97.0M
-$197.0M
-$100.0M
-$91.0M
Free cash flow
-$45.0M
-$98.0M
-$198.0M
-$101.0M
-$92.0M
Total assets
$1.2B
$1.3B
$1.3B
$1.5B
$1.2B
Total liabilities
$1.6B
$1.5B
$1.5B
$1.6B
$1.2B
Stockholders' equity
-$376.0M
-$291.0M
-$236.0M
-$80.0M
$10.0M
Cash and investments
$401.0M
$436.0M
$534.0M
$737.0M
$447.8M
Total debt
—
—
—
$36.0M
$33.8M

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report
Acquisition or sale of assets, Results of operations, Exit or restructuring costs
 Nov 3, 2026 Oct 30, 2026
8-K Current report
Other events
 Oct 19, 2026 Oct 19, 2026
8-K Current report
Material agreement
 Oct 14, 2026 Oct 8, 2026
8-K Current report
Material agreement
 Oct 7, 2026 Oct 6, 2026
8-K Current report
Other events
 Sep 17, 2026 Sep 17, 2026

All 1001 Ultragenyx Pharmaceutical Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.